Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

doi:10.1038/s41375-026-02885-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

Leukemia - 1 Apr 2026

Rolles Benjamin, Filho Cilomar Martins de Oliveira, Fergusson Nathan, Bewersdorf Jan Philipp, Keating Julia, Perkins Cecelia, Schwede Matthew, England James, Luskin Marlise R, DeAngelo Daniel J, Shimony Shai, Faiz Mifra, Hillerbrand Addison C, Kim Chulwoo, Weeks Lachelle D, Waldman Lauren, Wazir Mohammed, How Joan, Marneth Anna E, Liu Yiwen, Aryee Martin J, Rampal Raajit, Tsai Harrison K, Gotlib Jason, Gupta Vikas, Stahl Maximilian, Mullally Ann

Abstract excerpt

While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we analyzed data from 1540 patients treated at four specialized cancer centers. Among them, 1429 had wildtype TP53 and 111 had mutations in the TP53 gene. At first MPN diagnosis,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to TP53 gene

Share to Mutation

Share to Myeloproliferative Disorders

Share to Prognosis

Share to Risk Assessment

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41735484
DOI: 10.1038/s41375-026-02885-7
PMCID: PMC13143329

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.PMID 41735484Read ↗

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.Semantic proximity Read ↗

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.Semantic proximity Read ↗

Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases.Semantic proximity Read ↗

Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study.Semantic proximity Read ↗

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsSemantic proximity Read ↗

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.Semantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

Overall survival in TP53-mutated AML and MDS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.